logo
  

Novartis Reports Post Hoc Analysis From Phase III IRIDIUM Study

Novartis (NVS) presented post hoc analysis from the pivotal Phase III IRIDIUM study, which showed that high-dose, once-daily Enerzair Breezhaler significantly reduced both moderate-or-severe and severe asthma exacerbation rates in patients whose asthma is uncontrolled on medium- or high-dose long-acting beta2-agonist/inhaled corticosteroids, when compared with a once-daily medium-dose of the same treatment. The study also showed the safety profile for high-dose Enerzair Breezhaler was in line with previous studies in the Phase III/IIIb PLATINUM clinical development program.

IRIDIUM was a phase III, multicenter, randomized, double-blind, parallel-group study, designed to compare the efficacy and safety of IND/GLY/MF with IND/MF in patients with asthma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bea Lydecker's Naturals, Inc. is recalling six Living Free brand dietary supplement products citing undeclared soy lecithin, the U.S. Food and Drug Administration said. According to the agency, the labels declare lecithin but do not declare soy lecithin. Investment banking major Morgan Stanley plans to block employees and clients who are not fully vaccinated against COVID-19 from entering its New York offices, the Financial Times reported citing an internal memo. The policy is expected to come into effect on July 12, and all unvaccinated employees will lose building access from then onwards. Oklahoma City, Oklahoma -based Prairie Wolf Spirits, Inc. is recalling certain Prairie Wolf Distillery hand sanitizer packaged in containers that resemble water bottles, the U.S. Food and Drug Administration said. The product poses a risk of ingestion. The recall involves all lots of Prairie Wolf Distillery hand sanitizer packaged in 16.9 fluid ounce and 20 fluid ounce containers.
Follow RTT